Back to dashboard
All PlansAdministrativeLow impact

[California] Lenalidomide is now available with end‑to‑end REMS support

Anthem BCBS·CA · Oncology, Hematology·Provider Bulletin
Effective date
Not stated
We identified it
May 3, 2026
Days to comply
—

Summary

Lenalidomide (a cancer medication) is now available with end-to-end REMS (Risk Evaluation and Mitigation Strategy) support in California. This provides streamlined access and safety monitoring for this high-risk medication used primarily in oncology.

Action Required

Action needed
Oncology practices prescribing lenalidomide should contact Anthem California for details on the new REMS support program. Review current lenalidomide prescribing and billing workflows to determine if enhanced REMS support can improve patient access or reduce administrative burden.

Related policy hubs